GSK_ Annual_Report_2021-22

Notes to the Consolidated Financial Statements for the year ended March 31, 2022 229 Note 28 : Movement in provisions ( ` in lakhs ) Pricing matters Refer note (i) Long term Incentive Plan Refer note (ii) Divestment / Restructuring Refer note (i) Expected Sales Returns Refer note (iii) Associated cost to Impairment and cost to sell Severance pay Provision for Zinetac (Other costs) Refer note (iv) Others Refer note (v) Balance as at April 1, 2021 123,96.15 13,04.42 1,92.96 72,87.28 16,41.00 19,38.39 7,05.00 157,20.84 Add: Provision during the year - 6,54.48 - 42,13.10 - - - 85,70.00 Less: Amounts utilised/reversed during the year - 9,63.18 - 23,16.63 11,41.00 15,72.05 46.47 19,45.40 Balance as at March 31, 2022 123,96.15 9,95.72 1,92.96 91,83.75 5,00.00 3,66.34 6,58.53 223,45.44 Balance as at April 1, 2020 123,96.15 10,06.07 1,92.96 52,33.04 64,10.87 31,51.74 18,91.00 116,11.96 Add: Provision during the year - 12,85.06 - 75,54.27 - - - 29,23.00 Add: Restated as per IND AS 103 (Refer Note 57) - - - - - - - 20,44.65 Less: Amounts utilised/reversed during the year - 9,86.71 - 55,00.03 47,69.87 12,13.35 11,86.00 8,58.77 Balance as at March 31, 2021 123,96.15 13,04.42 1,92.96 72,87.28 16,41.00 19,38.39 7,05.00 157,20.84 Notes: (i) Pricing matters and Divestment/ Restructuring: Provision for pricing matters and Divestment/ Restructuring made for probable liabilities/ claims arising out of pending dispute, litigations/ commercial transactions with statutory authorities/ third parties. The outflow with regard to the said matters depends on the exhaustion of remedies available to the Group under the law and hence the Group is not able to reasonably ascertain the timing of the outflow. Also refer notes 42 and 44. (ii) Long term incentive plan: Refer note 54. (iii) Expected sales returns: This represents provision made for expected sales returns. Revenue is adjusted for the expected value of returns. (iv) Provision for Zinetac (Other costs) : This represents provision for incidental costs and other related costs for the Zinetac inventory pending to be destroyed. (v) Consists mainly of provisions in respect of indirect tax matters. Note 29 : Revenue from operations ( ` in lakhs ) Year ended March 31, 2022 Year ended March 31, 2021 A. Sale of products Sale of products 3264,08.12 2895,74.53 3264,08.12 2895,74.53 B. Other operating revenue Service income 12,70.67 20,42.25 Manufacturing charges recovery - 3,66.06 Others 1,24.13 5,77.33 13,94.80 29,85.64 Total Revenue from operations (A + B) 3278,02.92 2925,60.17 C. R evenue from contracts with customers disaggregated based on geography (Refer Note 52) Revenue from the Country of Domicile- India 3196,13.20 2910,96.87 Revenue from foreign countries 81,89.72 14,63.30 3278,02.92 2925,60.17 D. Reconciliation of gross revenue with revenue from contracts with customers Gross revenue 3584,38.56 3094,87.94 Less: Trade discounts, volume rebates, etc. 320,30.44 199,13.41 Net revenue recognised from contracts with customers 3264,08.12 2895,74.53